A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF JEEVANIYA VATI (medicated tablet) AND GARBHA POSHANA VATI (medicated tablet)IN THE MANAGEMENT OF UPAVISTAKA W.S.R TO IUGR

A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF JEEVANIYA VATI AND GARBHA POSHANA VATI IN THE MANAGEMENT OF UPAVISTAKA W.S.R TO IUGR

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/01/016892

Enrollment

Registered

2019-01-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O365- Maternal care for known or suspected poor fetal growth

Interventions

Intervention1: JEEVANIYA VATI: JEEVANIYA VATI TWO TABLETS TWICE DAILY AFTER FOOD WITH MILK UPTO DELIVERY Control Intervention1: GARBHA POSHANA VATI: GARBHA POSHANA VATI TWO TABLETS TWICE DAILY AF

Eligibility

Inclusion criteria

Inclusion criteria: PREGNANT WOMEN AGED BETWEEN 18-35 YEARS BOTH PRIMI AND MULTIGRAVIDA PREGNANT WOMEN DIAGNOSED WITH UPAVISTAKA IN 28TH TO 32ND WEEKS OF GESTATIONAL AGE PREGNANT WOMEN DIAGNOSED WITH ASYMMETRIC IUGR

Exclusion criteria

Exclusion criteria: PATIENTS HAVING HISTORY OF ANY OTHER SYSTEMIC ILLNESS THAT MAY INTERFERE WITH THE COURSE OF TREATMENT

Design outcomes

Primary

Measure	Time frame
EFFICACY OF INTERVENTION OVER FETAL WEIGHT GAINTimepoint: From 7 month to date of delivery for 3 months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR PAPIYA JANA

SRI KALABYRAVESHWARA SWAMY AYURVEDIC MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE

drpapiya@gmail.com9886716216

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026